Therapeutic Solutions International Subsidiary Immunotherapy Company Res Nova Bio, Inc. Announces Positive Data on First Four Advanced Cancer Patients Treated with FloraStilbene™

Rhea-AI Summary

Therapeutic Solutions International, Inc. (TSOI) successfully treated four advanced cancer patients with FloraStilbene™, a drug comprising the abortion pill's active ingredient and pterostilbene. No adverse events were observed, and clinical signals of tumor response were noted. The drug has shown efficacy in stimulating immune responses in animal models of various cancers, with emphasis on triple negative breast tumor models. The use of pterostilbene for cancer immunotherapy was patented by the company. The data from this treatment will serve as the basis for future clinical trials for FDA sales approval. The company has the support of leaders of the Pro-Life Movement. The rapid translation of FloraStilbene™ from a laboratory discovery to a compounded drug speaks volumes to the power of the company's team.

Clinical Stage Oncology Biotech Leverages Active Ingredient in Abortion Pill to Induce Immunity to Cancer

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today that its Subsidiary Company Res Nova Biologics, successfully treated four advanced cancer patients with FloraStilbene™. The patients had no adverse events from drug administration and clinical signals of tumor response were observed. All patients have been followed-up with for more than three months.

FloraStilbene™ is a drug comprising of a proprietary formulation of the abortion pill’s active ingredient (RU486) and pterostilbene. The drug is manufactured by Compounding Pharmacy Cure Stat¹ and is available by prescription under Right To Try. Previously, the Company has demonstrated efficacy of FloraStilbene in stimulating immune responses in animal models of various cancers, with an emphasis on triple negative breast tumor models².

The use of pterostilbene for cancer immunotherapy was patented by Therapeutic Solutions International in 2017³, subsequent to which, numerous independent groups have shown the ability of this compound to block prostate⁴, breast⁵, melanoma⁶, glioma⁷, and lung cancers⁸.

“This is a major step forward in Res Nova’s development plan for FloraStilbene™. These data, combined with existing preclinical and animal studies will serve as the basis for future clinical trials which will provide the basis for FDA sales approval,” said Dr. James Veltmeyer, Chief Medical Officer and the Physician who administered the drug. “From an ethical perspective, we are proud to have the support of several major leaders of the Pro-Life Movement including Bishop Joseph L Coffey (of the Military Archdiocese)⁹ and Dr. George Delgado (Inventor of the Abortion Pill Reversal) who sit on the Company’s Advisory Board¹⁰.”

“The brilliant founders of Res Nova, with a miraculous stroke of genius, are turning a drug that destroys life into a 'weapon' that destroys cancer to saves lives,” said Deacon Keith Esshaki, Member of the Company’s Advisory Board.

“The rapid translation of FloraStilbene™ from a laboratory discovery to a compounded drug speaks volumes to the power of the team that Ms Ramos has assembled,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “Through leveraging relationships and resources provided by TSOI, we anticipate accelerated availability of FloraStilbene™ to the multitude of drug resistant cancer patients.”

“Breast cancer is a major epidemic for which novel treatments and research directions are urgently needed. We are thankful to our colleagues but most importantly to the brave patients who participated in this study, which we anticipate will be the foundation for a paradigm shifting approach to this dreadful disease,” said Famela Ramos, President and CEO of Res Nova Bio, Inc.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™ (yahoo.com)
2 Therapeutic Solutions International Subsidiary Res Nova Bio Inc Discovers New Mechanism of Action for Breast Cancer Immunotherapy Adjuvant FloraStilbene™ | BioSpace
3 US9682047B2 - Augmentation of oncology immunotherapies by pterostilbene containing compositions - Google Patents
4 Inhibition of miR-20a by pterostilbene facilitates prostate cancer cells killed by NK cells via up-regulation of NKG2D ligands and TGF-β1down-regulation: Heliyon
5 Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells | Anticancer Research (iiarjournals.org)
6 Pterostilbene supresses inflammation-induced melanoma metastasis by impeding neutrophil elastase-mediated thrombospondin-1 degradation – ScienceDirect
7 Pterostilbene promotes mitochondrial apoptosis and inhibits proliferation in glioma cells | Scientific Reports (nature.com)
8 Pterostilbene exerts anticancer activity on non-small-cell lung cancer via activating endoplasmic reticulum stress | Scientific Reports (nature.com)
9 Bishop Coffey - Archdiocese for the Military, USAArchdiocese for the Military, USA (milarch.org)
10 Res Nova Biologics Recruits Abortion Pill Reversal Founder to Scientific Advisory Board (yahoo.com)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240103410863/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Therapeutic Solutions International, Inc. (TSOI).

What is the drug used to treat advanced cancer patients?

The drug used is FloraStilbene™, which comprises the abortion pill's active ingredient and pterostilbene.

What are the observed clinical signals of tumor response in patients treated with FloraStilbene™?

The patients treated with FloraStilbene™ showed no adverse events from drug administration and clinical signals of tumor response were observed.

What is the basis for future clinical trials and FDA sales approval for FloraStilbene™?

The data from the treatment of advanced cancer patients will serve as the basis for future clinical trials and FDA sales approval for FloraStilbene™.

Who patented the use of pterostilbene for cancer immunotherapy?

Therapeutic Solutions International patented the use of pterostilbene for cancer immunotherapy.

Who supports the company from the Pro-Life Movement?

The company has the support of several major leaders of the Pro-Life Movement including Bishop Joseph L Coffey and Dr. George Delgado.

Who is the President and CEO of Therapeutic Solutions International?

The President and CEO of Therapeutic Solutions International is Timothy Dixon.

What is the name of the company's Subsidiary Company that treated advanced cancer patients?

The Subsidiary Company that treated advanced cancer patients is Res Nova Biologics.